Myeloma Therapy Supplement
Historically, multiple myeloma, the second most common hematologic malignancy in the US, has been difficult to manage. Hematologists/oncologists are more likely to encounter patients with myeloma, as an analysis of population-based cancer registries in nine countries indicates that the burden (number of incident cases) of this disease has increased. The three articles in this supplement discuss tailoring initial treatment for newly diagnosed myeloma patients who are eligible for transplantation; emerging induction therapies and newer regimens for newly diagnosed patients who will not undergo transplant; and tailoring treatment for patients with relapsed/refractory myeloma, including clinical data on NCCN-recommended therapies.
Essentials for Tailoring Multiple Myeloma Therapy
Supported by an educational grant from Millennium Pharmaceuticals, Inc.
Historically, multiple myeloma, the second most common hematologic malignancy in the US, has been difficult to manage. Hematologists/oncologists are more likely to encounter patients with myeloma, as an analysis of population-based cancer registries in nine countries indicates that the burden (number of incident cases) of this disease has increased. The three articles in this supplement discuss tailoring initial treatment for newly diagnosed myeloma patients who are eligible for transplantation; emerging induction therapies and newer regimens for newly diagnosed patients who will not undergo transplant; and tailoring treatment for patients with relapsed/refractory myeloma, including clinical data on NCCN-recommended therapies.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
